Ridge Diagnostics, Inc. and Ameritox, Ltd. Enter Into Licensing Agreement for Depression Biomarker Blood Test

SAN DIEGO & BALTIMORE--(BUSINESS WIRE)--Ridge DiagnosticsTM, Inc., a neurodiagnostic company, announced today it has entered into an exclusive agreement with AmeritoxSM, Ltd., a leader in medication monitoring, for the license rights to its proprietary developmental blood test MDDScore TM, a multiple biomarker analysis for Major Depressive Disorder (MDD) for primary care and pain physicians. As part of the agreement, Ameritox has agreed to make an undisclosed equity investment in Ridge and commit to a next-stage clinical development program.